Search Results
Dr. Weber on Discontinuing Immunotherapy in Melanoma
Dr. Weber on Selecting Immunotherapy for Patients With Melanoma
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
Metastatic Melanoma: The Immunotherapy Approach
Dr. Weber on FDA Approval of Pembrolizumab for Stage III Melanoma
Limiting duration of treatment with checkpoint inhibitors: the data
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma
Long-Term Results for Immunotherapy in Melanoma
Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma
Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma
Dr. Jeffrey Weber on Potential Breakthrough "Cures" in Melanoma
Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma
